A5102745348- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Liver Disease and Transplantation
- Inflammatory Biomarkers in Disease Prognosis
- Liver Disease Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
- Metastasis and carcinoma case studies
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
General Hospital of Shenyang Military Region
2017-2025
Chinese PLA General Hospital
2024-2025
Seventh People's Hospital of Shanghai
2025
Shanghai University of Traditional Chinese Medicine
2025
Jiangsu Cancer Hospital
2015-2024
Shanghai Medical College of Fudan University
2024
Nanjing Medical University
2019-2024
PLA Academy of Military Science
2024
Lanzhou Institute of Husbandry and Pharmaceutical Sciences
2024
Ministry of Agriculture and Rural Affairs
2024
High tumor mutational burden (TMB-H) is correlated with enhanced objective response rate (ORR) and progression-free survival (PFS) for certain cancers receiving immunotherapy. This study aimed to investigate the safety efficacy of toripalimab, a humanized programmed death-1 (PD-1) antibody, in advanced gastric cancer (AGC), predictive benefit TMB PD-L1.
Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). In the case drug-related grade ≥3 or selected prolonged 2 adverse events (AEs), dose can be reduced by 10 mg decrements to a minimum 20 mg. Here, we evaluate influence afatinib reduction on AEs, pharmacokinetics and progression-free survival (PFS) in phase III LUX-Lung 3 6 (LL3/6) trials.Treatment-naïve patients with advanced NSCLC LL3 (global) LL6 (China, Thailand, South...
Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize chemotherapy-induced nausea and vomiting (CINV) control patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination selective NK1 receptor antagonist, netupitant (300 mg), the pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 has shown superior CINV prevention compared with PALO cisplatin anthracycline/cyclophosphamide-based settings....
Aim: To compare the efficacy, safety, and tolerability of abemaciclib plus endocrine therapy (ET) versus ET alone in postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC) from China, Brazil, India, South Africa. Methods: This randomized, double-blind, phase III study was conducted between 9 December 2016 29 March 2019. Postmenopausal HR-positive, HER2-negative ABC no prior systemic an setting (cohort A) or...
BACKGROUND: Whether it is effective and safe to extend the time window of intravenous thrombolysis up 24 hours after last known well unknown. We aimed determine efficacy safety tenecteplase in Chinese patients with acute ischemic stroke due large/medium vessel occlusion within an extended window. METHODS: Patients presenting 4.5 from well, a favorable penumbral profile associated occlusion, were randomized 1:1 either 0.25 mg/kg or best medical treatment. A was defined as hypoperfusion lesion...
8016 Background: A is an oral, irreversible, ErbB Family Blocker, blocking signaling from EGFR (ErbB1), HER2 (ErbB2) and ErbB4. was superior to first-line pemetrexed/cisplatin in a global phase III trial (LUX-Lung 3) M+ NSCLC. This study compared the safety efficacy of with GC Asian pts. Methods: The conducted countries. Following central testing for mutations (TheraScreen RGQ PCR kit), 364 pts (stage IIIB/IV, PS 0–1, chemo-naïve) were randomized 2:1 (A: 242; GC: 122) daily 40 mg or IV...
7520 Background: The OPTIMAL study demonstrated significant superiority for E versus GC in terms of progression-free survival (PFS), objective response rate, tolerability and quality life (QoL) first-line advanced NSCLC patients with EGFR activating mutations (Act Mut+). Here we report OS data from (ClinicalTrials.gov NCT00874419). Methods: Chemotherapy-naive Chinese Act Mut+, ECOG performance status (PS) 0–2 measurable disease were randomized to (150 mg/day), or GC, stratified by histology,...
Background: Recent studies have shown that the presence of systemic inflammation correlates with poor survival in various types cancers. This study investigated usefulness a novel inflammation-based prognostic system, using combination neutrophil lymphocyte ratio (NLR) and platelet (PLR), collectively named CNP, for predicting patients esophageal squamous cell carcinoma (ESCC). Materials methods: The CNP was calculated on basis data obtained day admission: both elevated NLR (>3.45) PLR...
Molecular markers involved in DNA repair can help to predict survival gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed advanced tumour samples using real-time quantitative PCR 76 a modified FOLFOX (biweekly oxaliplatin folinic acid) regimen. Median time low ERCC1 was significantly longer than those high (15.8 vs 6.2 months; P<0.0001). Patients TS had (12.2 10.1...
Abstract This paper presents a novel design for broadband coaxial transition featuring large inner conductor radius ratio. To establish the equivalence between two-port matching network and even mode of symmetrical power splitting network, an equivalent circuit model ideal Tee junction is proposed. Subsequently, highly integrated impedance developed by employing double strategy. By adopting symmetrical, in-phase, equal-amplitude feeding strategy, challenges associated with spurious...
1003 Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine showed clinically meaningful benefits and acceptable tolerability in patients (pts) with HER2+ metastatic breast cancer (MBC) phase 1 2 studies. Methods: This open-label, multicenter, randomized 3 study enrolled MBC pts after trastuzumab taxanes, and/or anthracyclines. Up to two prior lines of chemotherapy (chemo) for disease were allowed. Pts randomly assigned (1:1) receive pyrotinib 400 mg or lapatinib 1250...
8019^ Background: Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective/non-randomized studies, however, this yet to be prospectively evaluated a randomized trial. LL5 is trial, which assessed the efficacy irreversible ErbB family blocker, afatinib (A), addition P NSCLC pts prior benefit from reversible tyrosine kinase inhibitors (E/G) and A. Methods: In open-label, global phase III who had failed ≥1 line CT E/G (after ≥12 wks...
1028 Background: RC48-ADC is a novel HER2-targeting antibody–drug conjugate (ADC) that selectively delivers anticancer agent MMAE into HER2-overexpressing tumor cells. A Phase I study (NCT02881138) has preliminary demonstrated well tolerated and clear clinical activity in patients (pts) with metastatic breast cancer (MBC). Methods: This was phase Ib, open-label, multicenter 3 dose cohorts (1.5, 2.0 2.5mg/kg, Q2W). Eligible pts (18-70 years) were assessed HER2-positive (IHC 2+/FISH +, or IHC...
9112 Background: Our preclinical study suggested combination of PD-1 monoclonal antibody SHR-1210 and VEGFR 2 inhibitor apatinib significantly improved antitumor effects. This was an open-label, multi-center, phase 1/2 intravenous plus oral in patients with advanced NSCLC. Here, we reported preliminary efficacy safety outcomes wild‐type EGFR ALK. Methods: In dose-escalation phase, non-squamous NSCLC (pts) previously treated at least 2nd line chemotherapy were enrolled to explore dose levels...